EAU 2017 | What does the earlier application of immune-oncology agents mean for urological cancer teams?
Joaquim Bellmunt
Joaquim Bellmunt, MD, PhD, from the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary teams at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Bellmunt highlights the new results on immune-oncological agents presented at this conference, and that the treatment of urological cancers requires a multidisciplinary team approach.He says it is crucial that the community treating genitourinary patients is aware of the treatment advances, and how to manage these in the setting of earlier treatments.
Similar topics
Related videos

Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles

Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa

Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen

TROPHY-U-01: Initial findings
Scott Tagawa

Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
More from Joaquim Bellmunt